Literature DB >> 16832589

Rehabilitation vs drug therapy for urge urinary incontinence: short-term outcome.

Rachel Kafri1, Rami Langer, Zeevi Dvir, Michal Katz-Leurer.   

Abstract

The objective of this study was to compare the short-term effectiveness of rehabilitation treatment with a standard drug treatment for urge urinary incontinence (UUI). The study design includes parallel clinical trial in an outpatient urogynecologic clinic setting. The subjects were 44 women who suffered from UUI and who were systematically assigned to a rehabilitation group (REH) (N=24) or a medication group (MED) (N=20). The intervention for REH was consisted of five visits during a 3-month period of pelvic floor muscle training and behavioral training, whereas for MED was extended release oxybutynin at 5 mg/day, for 3 months. The urinary symptoms considered were frequency of voiding per day and night (freq/day and freq/night), number of incontinent episodes per week based on a bladder diary, and data based on the Incontinence Quality of Life Instrument (I-QoL). In the within-group comparison, both groups had improved significantly over time with respect to urinary symptoms and I-QoL (p<0.01). In addition, there was a significant group-time interaction effect on freq/day. While REH improved during the 3-month follow-up period, the MED group deteriorated to mean baseline value (p<0.01). A significant negative association was found between the urinary symptoms and the I-QoL at the end of follow-up (r (p)=-0.35 to -0.62, p<0.05). Three months after the intervention, both groups maintained the achievements of the intervention period. In addition, the REH group demonstrated additional improvement in mean freq/day while the condition of MED patients deteriorated to baseline values.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16832589     DOI: 10.1007/s00192-006-0163-1

Source DB:  PubMed          Journal:  Int Urogynecol J Pelvic Floor Dysfunct


  18 in total

1.  Effect of pelvic floor muscle contraction on vesical and rectal function with identification of puborectalis-rectovesical inhibitory reflex and levator-rectovesical excitatory reflex.

Authors:  A Shafik; O El-Sibai
Journal:  World J Urol       Date:  2001-08       Impact factor: 4.226

2.  The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society.

Authors:  Paul Abrams; Linda Cardozo; Magnus Fall; Derek Griffiths; Peter Rosier; Ulf Ulmsten; Philip van Kerrebroeck; Arne Victor; Alan Wein
Journal:  Am J Obstet Gynecol       Date:  2002-07       Impact factor: 8.661

Review 3.  The clinical significance of the urodynamic investigation in incontinence.

Authors:  Y Homma
Journal:  BJU Int       Date:  2002-09       Impact factor: 5.588

4.  Urinary incontinence in women.

Authors: 
Journal:  Obstet Gynecol       Date:  2005-06       Impact factor: 7.661

Review 5.  Drug therapy of urinary urge incontinence: a systematic review.

Authors:  Guenther Haeusler; Harald Leitich; Mick van Trotsenburg; Alexandra Kaider; Clemens B Tempfer
Journal:  Obstet Gynecol       Date:  2002-11       Impact factor: 7.661

6.  Improved quality of life in patients with overactive bladder symptoms treated with solifenacin.

Authors:  Con J Kelleher; Linda Cardozo; Christopher R Chapple; Francois Haab; Arwin M Ridder
Journal:  BJU Int       Date:  2005-01       Impact factor: 5.588

7.  Evaluation of a new once-daily formulation of oxbutynin for the treatment of urinary urge incontinence. Ditropan XL Study Group.

Authors:  D M Gleason; J Susset; C White; D R Munoz; P K Sand
Journal:  Urology       Date:  1999-09       Impact factor: 2.649

8.  Discrepancy in patient and physician perception of patient's quality of life related to urinary symptoms.

Authors:  Larissa V Rodríguez; Daniel S Blander; Frederick Dorey; Shlomo Raz; Philippe Zimmern
Journal:  Urology       Date:  2003-07       Impact factor: 2.649

9.  Quality of life of women with urinary incontinence: further development of the incontinence quality of life instrument (I-QOL)

Authors:  D L Patrick; M L Martin; D M Bushnell; I Yalcin; T H Wagner; D P Buesching
Journal:  Urology       Date:  1999-01       Impact factor: 2.649

Review 10.  The wet patient: understanding patients with overactive bladder and incontinence.

Authors:  Scott Serels
Journal:  Curr Med Res Opin       Date:  2004-06       Impact factor: 2.580

View more
  6 in total

1.  CUA guideline on adult overactive bladder.

Authors:  Jacques Corcos; Mikolaj Przydacz; Lysanne Campeau; Gary Gray; Duane Hickling; Christiane Honeine; Sidney B Radomski; Lynn Stothers; Adrian Wagg; Frcp Lond
Journal:  Can Urol Assoc J       Date:  2017-05-09       Impact factor: 1.862

2.  Randomized trial of a comparison of rehabilitation or drug therapy for urgency urinary incontinence: 1-year follow-up.

Authors:  Rachel Kafri; Daniel Deutscher; Jeffrey Shames; Jacob Golombp; Itshak Melzer
Journal:  Int Urogynecol J       Date:  2012-11-17       Impact factor: 2.894

Review 3.  Update on behavioral and physical therapies for incontinence and overactive bladder: the role of pelvic floor muscle training.

Authors:  Kathryn L Burgio
Journal:  Curr Urol Rep       Date:  2013-10       Impact factor: 3.092

Review 4.  Pelvic floor muscle training added to another active treatment versus the same active treatment alone for urinary incontinence in women.

Authors:  Reuben Olugbenga Ayeleke; E Jean C Hay-Smith; Muhammad Imran Omar
Journal:  Cochrane Database Syst Rev       Date:  2015-11-03

5.  Efficacy of pelvic floor muscle training in women with overactive bladder syndrome: a systematic review.

Authors:  Silvia Monteiro; Cassio Riccetto; Angélica Araújo; Laryssa Galo; Nathália Brito; Simone Botelho
Journal:  Int Urogynecol J       Date:  2018-04-11       Impact factor: 2.894

6.  Rehabilitation versus drug therapy for urge urinary incontinence: long-term outcomes.

Authors:  Rachel Kafri; Jeffrey Shames; Meir Raz; Michal Katz-Leurer
Journal:  Int Urogynecol J Pelvic Floor Dysfunct       Date:  2007-06-05
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.